...
首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
【24h】

Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.

机译:拉诺前列素在食蟹猴中的药代动力学。第一次沟通:单次静脉,口服或局部眼部给药。

获取原文
获取原文并翻译 | 示例
           

摘要

Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2a- isopropyl ester, CAS 130209-82-4 PhXA41, Xalatan) is a prodrug used for reduction of the intraocular pressure in the treatment of glaucoma. The pahrmacokinetics of this drug was studied in the cynomolgus monkey after intravenous, oral and topical administration of 9 beta-[3H] labelled latanoprost. The plasma profile of radioactivity from HPLC separation of samples obtained after intravenous as well as topical administration on the eyes showed a rapid and complete hydrolysis of the ester. The pharmacologically active acid of latanoprost showed a maximum concentration 5 min post topical administration and an elimination half-life of about 10 min. Tertiary butyldimethylsilyl derivatives were prepared of the radioactive fractions collected from the HPLC column. The derivatives were analysed by gas chromatography-mass spectrometry (GC-MS). After oral administration no latanoprost and very little of its acid was present in plasma, indicating a first-pass metabolism resulting in more polar compounds. Based on the retention times on the HPLC and GC and on a mass spectrum similar to the acid of latanoprost but 28 daltons lower, the main metabolite in urine and faeces was identified as the 1,2-dinor acid of latanoprost. In a similar way a more polar fraction from urine was identified as the 1,2,3,4-tetranor metabolite of the acid of latanoprost. The tissue distribution after i.v. and topical administration was similar with organs of metabolism (liver) and elimination (kidney) containing the highest concentrations. After topical application much of the dose was found in the anterior ocular tissues but not in the posterior parts of the eye. In conclusion, latanoprost is a prodrug which in vivo rapidly is hydrolysed to the corresponding free acid. The acid of latanoprost has a short half-life in plasma and is extensively metabolised mainly through beta-oxidation before it is excreted into the urine and faeces.
机译:拉坦前列素(13,14-dihydro-15(R)-17-苯基-18,19,20-trinor-PGF2a-异丙酯,CAS 130209-82-4 PhXA41,Xalatan)是用于降低眼压的前药在治疗青光眼。静脉,口服和局部施用9β-[3H]标记的拉坦前列素后,在食蟹猴中研究了该药物的药代动力学。在静脉内以及眼睛局部给药后,通过HPLC分离获得的样品的HPLC放射性血浆分布表明,该酯快速而完全地水解了。拉坦前列素的药理活性酸在局部给药后5分钟显示最大浓度,消除半衰期约为10分钟。从HPLC柱收集的放射性级分制备了叔丁基二甲基甲硅烷基衍生物。通过气相色谱-质谱法(GC-MS)分析衍生物。口服后,血浆中不存在拉坦前列素,其酸也很少,这表明首过代谢会产生更多极性化合物。根据HPLC和GC上的保留时间以及与拉坦前列素酸相似但低28道尔顿的质谱图,尿液和粪便中的主要代谢产物被确定为拉坦前列素的1,2-二价酸。以类似的方式,尿液中极性更大的部分被鉴定为拉坦前列素酸的1,2,3,4-丁诺代谢产物。静脉注射后的组织分布局部给药与最高浓度的代谢器官(肝脏)和排泄器官(肾脏)相似。局部应用后,大部分剂量在眼前组织中发现,但在眼后部未发现。总之,拉坦前列素是一种前药,其在体内迅速被水解成相应的游离酸。拉坦前列素的酸在血浆中的半衰期很短,在被排泄到尿液和粪便之前,主要通过β氧化被广泛代谢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号